Emerging utility of once-weekly exenatide in patients with type 2 diabetes
Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidenc...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/90df0cef555e4836a09f0443ce732411 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.Keywords: incretin, glucagon-like peptide, hyperglycemia, glucose lowering |
|---|